Dementia and neurocognitive disorders最新文献

{"title":"Effects of Cognitive and Depressive Status on Empathy in Healthy Elderly, Amnestic MCI, and Dementia of the Alzheimer's Type.","authors":"Seonyeong Yang, Sun Hwa Lee, Jaeho Kim, Soo-Jin Cho, Yeonwook Kang","doi":"10.12779/dnd.2025.24.1.54","DOIUrl":"10.12779/dnd.2025.24.1.54","url":null,"abstract":"<p><strong>Background and purpose: </strong>Empathy comprises cognitive and emotional components. However, the impairments in empathy among individuals with mild cognitive impairment (MCI) and dementia of the Alzheimer's type (DAT) are not well understood, particularly in the context of depression, which may exacerbate these deficits. This study aimed to evaluate the effects of neurodegeneration and depression on empathetic abilities.</p><p><strong>Methods: </strong>The study included 31 healthy elderly (HE) individuals, 30 patients with amnestic multi-domain MCI (amMCI), and 30 patients with DAT. Empathy was assessed using the Korean-Multifaceted Empathy Test (K-MET), and the Interpersonal Response Index (IRI). Participants were classified as depressed or non-depressed using the Geriatric Depression Scale. A two-way MANOVA was conducted to examine differences in empathy based on group and depressive status.</p><p><strong>Results: </strong>A significant interaction between group and depressive status was found for both cognitive and emotional empathy on the K-MET, but not on the IRI. In the depressed group, cognitive empathy scores were lower in the order of HE, amMCI, and DAT. Similarly, in the non-depressed group, the HE group performed better than both amMCI and DAT, with no significant difference between the latter two. Regarding emotional empathy, the depressed HE group scored higher than both amMCI and DAT, with no significant difference between these groups. In the non-depressed group, emotional empathy declined in the order of HE, amMCI, and DAT.</p><p><strong>Conclusions: </strong>These findings indicate that both neurodegeneration and depression significantly impair empathetic abilities, with declines in cognitive and emotional empathy evident at the MCI stage, regardless of depressive status.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"24 1","pages":"54-68"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracking Cognitive Trajectories in Mild Cognitive Impairment Using a Machine Learning Technique of Subtype and Stage Inference.","authors":"Hui Jin Ryu, Kyoung Ja Kwon, Yeonsil Moon","doi":"10.12779/dnd.2025.24.1.44","DOIUrl":"10.12779/dnd.2025.24.1.44","url":null,"abstract":"<p><strong>Background and purpose: </strong>Recognizing cognitive decline patterns in mild cognitive impairment (MCI) is crucial for early screening and preventive interventions. However, studies on the trajectory of individual cognitive functions in MCI are limited. Thus, the purpose of this study was to identify subtypes and stages of cognitive decline in MCI using a machine learning method.</p><p><strong>Methods: </strong>A total of 944 subjects consisting of those who were cognitively normal and those with MCI were enrolled. Fifteen neuropsychological tasks were used in the analysis. The optimal number of subtypes was determined based on the cross-validation information criterion. Fifteen stages of cognitive trajectory were estimated for each subtype.</p><p><strong>Results: </strong>The following three subtypes were identified: amnestic-verbal subtype, dysexecutive subtype, and amnestic-visual subtype. Of 723 (76.6%) subjects who had reached stage 1 at least, amnestic-verbal subtype accounted for the most (n=340, 47.0%), followed by dysexecutive subtype (n=253, 35.0%) and amnestic-visual subtype (n=130, 18%). The amnestic-verbal subtype had significantly more males (amnestic-verbal: 41.8%, dysexecutive: 31.2%, and amnestic-visual: 28.5%), younger subjects (amnestic-verbal: 72.01 years, dysexecutive: 74.43 years, and amnestic-visual: 75.06 years), higher educational years (amnestic-verbal: 11.06 years, dysexecutive: 9.53 years, and amnestic-visual: 9.79 years), lower Clinical Dementia Rating sum of boxes (amnestic-verbal: 1.40, dysexecutive: 1.61, and amnestic-visual: 1.71), and lower Korean-Instrumental Activities of Daily Living score (amnestic-verbal: 0.20, dysexecutive: 0.27, and amnestic-visual: 0.26).</p><p><strong>Conclusions: </strong>Three types of MCIs were extracted using SuStaIn. Pathways of MCI deterioration could be different. The amnestic type could be bisected based on whether episodic verbal or visual memory is degraded first.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"24 1","pages":"44-53"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Practice Guidelines for Dementia: Recommendations for the Pharmacological Treatment of Behavioral and Psychological Symptoms.","authors":"Gihwan Byeon, Dong Woo Kang, Yeshin Kim, Geon Ha Kim, Ko Woon Kim, Hee-Jin Kim, Seunghee Na, Kee Hyung Park, Young Ho Park, Jeewon Suh, Joon Hyun Shin, YongSoo Shim, YoungSoon Yang, Yoo Hyun Um, Seong-Il Oh, Sheng-Min Wang, Bora Yoon, Sun Min Lee, Juyoun Lee, Jin San Lee, Hak Young Rhee, Jae-Sung Lim, Young Hee Jung, Juhee Chin, Hyemin Jang, Yun Jeong Hong, Miyoung Choi, Jae-Won Jang","doi":"10.12779/dnd.2025.24.1.24","DOIUrl":"10.12779/dnd.2025.24.1.24","url":null,"abstract":"<p><strong>Background and purpose: </strong>Dementia often accompanies behavioral and psychological symptoms of dementia (BPSD), including agitation, aggression, depression, and psychosis, which impact patients' quality of life and caregiver burden. Effective management of BPSD is essential to support patient and caregiver well-being. This study presents evidence-based clinical practice guidelines for pharmacological treatments of BPSD in dementia, focusing on antipsychotics, antidepressants, cognitive enhancers, and other medications.</p><p><strong>Methods: </strong>This guideline was developed by the Korean Dementia Association's Quality Management Committee. Key questions were framed using the Population, Intervention, Comparison, Outcome methodology, followed by systematic literature searches. Randomized controlled trials were assessed for quality, and recommendations were graded based on evidence levels, employing the Grading of Recommendations, Assessment, Development and Evaluation system to establish strength and applicability.</p><p><strong>Results: </strong>Recommendations vary by medication type and symptom severity. Antipsychotics, such as risperidone, are conditionally recommended for managing aggression and psychosis in dementia, while antidepressants, specifically citalopram, are advised for agitation in Alzheimer's disease. Cognitive enhancers, including cholinesterase inhibitors and memantine, showed moderate efficacy for general BPSD improvement and rapid eye movement sleep behavior disorder in Lewy body dementia. Specific drugs, like pimavanserin, demonstrated efficacy in addressing psychosis in Alzheimer's patients.</p><p><strong>Conclusions: </strong>These guidelines provide a structured approach to pharmacological management of BPSD in dementia, addressing efficacy and safety profiles across drug categories. The recommendations emphasize personalized treatment plans to optimize therapeutic outcomes while minimizing risks, with a conditional approach suggested in cases with limited evidence.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"24 1","pages":"24-43"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine.","authors":"Yeshin Kim, Dong Woo Kang, Geon Ha Kim, Ko Woon Kim, Hee-Jin Kim, Seunghee Na, Kee Hyung Park, Young Ho Park, Gihwan Byeon, Jeewon Suh, Joon Hyun Shin, YongSoo Shim, YoungSoon Yang, Yoo Hyun Um, Seong-Il Oh, Sheng-Min Wang, Bora Yoon, Sun Min Lee, Juyoun Lee, Jin San Lee, Jae-Sung Lim, Young Hee Jung, Juhee Chin, Hyemin Jang, Miyoung Choi, Yun Jeong Hong, Hak Young Rhee, Jae-Won Jang","doi":"10.12779/dnd.2025.24.1.1","DOIUrl":"10.12779/dnd.2025.24.1.1","url":null,"abstract":"<p><strong>Background and purpose: </strong>This clinical practice guideline provides evidence-based recommendations for treatment of dementia, focusing on cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists for Alzheimer's disease (AD) and other types of dementia.</p><p><strong>Methods: </strong>Using the Population, Intervention, Comparison, Outcomes (PICO) framework, we developed key clinical questions and conducted systematic literature reviews. A multidisciplinary panel of experts, organized by the Korean Dementia Association, evaluated randomized controlled trials and observational studies. Recommendations were graded for evidence quality and strength using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.</p><p><strong>Results: </strong>Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson's disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. Both drug classes showed favorable safety profiles with manageable side effects.</p><p><strong>Conclusions: </strong>This guideline offers standardized, evidence-based pharmacologic recommendations for dementia management, with specific guidance on cholinesterase inhibitors and NMDA receptor antagonists. It aims to support clinical decision-making and improve patient outcomes in dementia care. Further updates will address emerging treatments, including amyloid-targeting therapies, to reflect advances in dementia management.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"24 1","pages":"1-23"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Combined Corticobasal Degeneration and Alzheimer's Disease Pathology: Clinical Presentation, and Diagnosis.","authors":"Seoyeon Baek, Sun Young Chae, Jae Seung Kim, Hyung-Ji Kim","doi":"10.12779/dnd.2025.24.1.69","DOIUrl":"10.12779/dnd.2025.24.1.69","url":null,"abstract":"","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"24 1","pages":"69-73"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing Alzheimer's Diagnosis and Management: The Dawn of Biomarker-Based Precision Medicine.","authors":"Hyuk Sung Kwon, Hyun-Jung Yu, Seong-Ho Koh","doi":"10.12779/dnd.2024.23.4.188","DOIUrl":"https://doi.org/10.12779/dnd.2024.23.4.188","url":null,"abstract":"<p><p>Alzheimer's disease (AD), a leading cause of dementia, presents a formidable global health challenge intensified by the aging population. This review encapsulates the evolving landscape of AD diagnosis and treatment with a special focus on the innovative role of fluid biomarkers. Pathologically, AD is marked by amyloid beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau, which lead to synaptic dysfunction, neuronal loss, and cognitive decline. These pathological changes, commencing decades before symptom onset, underscore the need for early detection and intervention. Diagnosis traditionally relies on clinical assessment, neuropsychological testing, and neuroimaging techniques. However, fluid biomarkers in cerebrospinal fluid and blood, such as various forms of Aβ, total tau, phosphorylated tau, and neurofilament light chain, are emerging as less invasive, cost-effective diagnostic tools. These biomarkers are pivotal for early diagnosis, differential diagnosis, disease progression monitoring, and treatment response evaluation. The treatment landscape is shifting toward personalized medicine, highlighted by advancements in Aβ immunotherapies, such as lecanemab and donanemab. Demonstrating efficacy in phase III clinical trials, these therapies hold promise as tailored treatment strategies based on individual biomarker profiles. The integration of fluid biomarkers into clinical practice represents a significant advance in AD management, providing the potential for early and precise diagnosis, coupled with personalized therapeutic approaches. This heralds a new era in combating this debilitating disease.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"23 4","pages":"188-201"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Validity of K-MoCA-22 Compared to K-MoCA-30 and K-MMSE for Screening MCI and Dementia.","authors":"Haeyoon Kim, Kyung-Ho Yu, Yeonwook Kang","doi":"10.12779/dnd.2024.23.4.236","DOIUrl":"https://doi.org/10.12779/dnd.2024.23.4.236","url":null,"abstract":"<p><strong>Background and purpose: </strong>Since the onset of the coronavirus disease 2019 pandemic, the Telephone-Montreal Cognitive Assessment (T-MoCA) has gained popularity as a remote cognitive screening tool. T-MoCA includes items from the original MoCA (MoCA-30), excluding those requiring visual stimuli, resulting in a maximum score of 22 points. This study aimed to assess whether the T-MoCA items (MoCA-22) demonstrate comparable discriminatory power to MoCA-30 and Mini-Mental State Examination (MMSE) in screening for mild cognitive impairment (MCI) and dementia.</p><p><strong>Methods: </strong>Participants included 233 cognitively normal (CN) individuals, 175 with MCI, and 166 with dementia. All completed the Korean-MoCA-30 (K-MoCA-30) and Korean-MMSE (K-MMSE), with the Korean-MoCA-22 (K-MoCA-22) scores derived from the K-MoCA-30 responses. A receiver operating characteristic (ROC) curve analysis was conducted.</p><p><strong>Results: </strong>K-MoCA-22 showed a strong correlation with K-MoCA-30 and a moderate correlation with K-MMSE. Scores decreased progressively from CN to MCI and dementia, with significant differences between groups, consistent with K-MoCA-30 and K-MMSE. The study also explored modified K-MoCA-22 index scores across 5 cognitive domains. ROC curve analysis revealed that the area under the curve (AUC) for K-MoCA-22 was significantly smaller than that for K-MoCA-30 in distinguishing both MCI and dementia from CN. However, no significant difference in AUC was found between K-MoCA-22 and K-MMSE, indicating similar discriminatory power. Additionally, the discriminability of K-MoCA-22 varied by education level.</p><p><strong>Conclusions: </strong>These results indicate that K-MoCA-22, although slightly less effective than K-MoCA-30, still shows good to excellent discriminatory power and is comparable to K-MMSE in screening for MCI and dementia.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"23 4","pages":"236-244"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD): A Cohort for Dementia Research and Ethnic-Specific Insights.","authors":"Hyemin Jang, Daeun Shin, Yeshin Kim, Ko Woon Kim, Juyoun Lee, Jun Pyo Kim, Hee Jin Kim, Soo Hyun Cho, Si Eun Kim, Duk L Na, Sang Won Seo","doi":"10.12779/dnd.2024.23.4.212","DOIUrl":"https://doi.org/10.12779/dnd.2024.23.4.212","url":null,"abstract":"<p><strong>Background and purpose: </strong>Dementia, particularly Alzheimer's disease, is a significant global health concern, with early diagnosis and treatment development being critical goals. While numerous cohorts have advanced dementia research, there is a lack of comprehensive data on ethnic differences, particularly for the Korean population. The Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD) aims to establish a large-scale, hospital-based dementia cohort to address this gap, with a focus on understanding disease progression, developing early diagnostics, and supporting treatment advancements specific to the Korean population.</p><p><strong>Methods: </strong>K-ROAD comprises multiple prospective cohorts. Participants underwent clinical evaluations, neuroimaging, and biomarker analysis, with data collected on a range of clinical and genomic markers.</p><p><strong>Results: </strong>As of December 2023, K-ROAD has recruited over 5,800 participants, including individuals across the Alzheimer's clinical syndrome, subcortical vascular cognitive impairment, and frontotemporal dementia spectra. Preliminary findings highlight significant ethnic differences in amyloid positivity, cognitive decline, and biomarker profiles, compared to Western cohorts.</p><p><strong>Conclusions: </strong>The K-ROAD cohort offers a unique and critical resource for dementia research, providing insights into ethnic-specific disease characteristics and biomarker profiles. These findings will contribute to the development of personalized diagnostic and therapeutic approaches to dementia, enhancing global understanding of the disease.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"23 4","pages":"212-223"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Late-Onset De Novo Huntington's Disease Diagnosed via ¹⁸F-FDG PET.","authors":"Jae Young Joo, Sun Young Chae, Jae Seung Kim, Hyung-Ji Kim","doi":"10.12779/dnd.2024.23.4.245","DOIUrl":"https://doi.org/10.12779/dnd.2024.23.4.245","url":null,"abstract":"","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"23 4","pages":"245-247"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lecanemab: Appropriate Use Recommendations by Korean Dementia Association.","authors":"Kee Hyung Park, Geon Ha Kim, Chi-Hun Kim, Seong-Ho Koh, So Young Moon, Young Ho Park, Sang Won Seo, Bora Yoon, Jae-Sung Lim, Byeong C Kim, Hee-Jin Kim, Hae Ri Na, YongSoo Shim, YoungSoon Yang, Chan-Nyoung Lee, Hak Young Rhee, San Jung, Jee Hyang Jeong, Hojin Choi, Dong Won Yang, Seong Hye Choi","doi":"10.12779/dnd.2024.23.4.165","DOIUrl":"https://doi.org/10.12779/dnd.2024.23.4.165","url":null,"abstract":"<p><p>Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations, administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"23 4","pages":"165-187"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}